drugset
drugset / Trial / NCT03074331

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

NCT03074331 ↗

Phase 3 Completed 130 enrolled Gilead Sciences
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection.

Timeline

Start
2017-03-23
Primary completion
2018-02-07
Completion
2018-02-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sofosbuvir Small molecule 400 mg Oral
Subject velpatasvir Other / unclassified 100 mg Oral

Indications

chronic hepatitis C virus infection